

CURRICULUM VITAE ET STUDIORUM

Name: **Angela Santoni**

Born : Nereto (TE) , February 21 ,1950

Citizenship: Italy

Address: home - 00184 ROMA, Via Baccina 32,

work- Department Molecular Medicine,

University of Rome "La Sapienza"

phone 39-6-44340632; fax 39-6-44340632

EDUCATION AND DEGREES

1972 Ph.D. in Biology, University of Perugia, Perugia, Italy

Graduation Score: 110/110 cum laude, July 27,1972

ACADEMIC POSITIONS

- 1972-73 Acting Assistant Professor, Institute of Hygiene, Medical School, University of Perugia, Perugia, Italy.
- 1974-75 Research Associate, Institute of Pharmacology, University of Perugia.
- 1975-77 Fogarty Fellow, Laboratory of Experimental Chemotherapy and Immunodiagnosis, NCI-NIH, Bethesda, MD.
- 1978-81 University Researcher, Chair of Virology, University of Perugia.
- 1982-83 Research Expert, Laboratory of Immunodiagnosis, NCI, NIH, Bethesda, MD, and Biological Response Modifiers Program, Biological Therapeutics Branch, Section of Natural Immunity, NCI, CRF, Frederick, MD.
- 1983-1986 University Researcher, Department of Experimental Medicine, University "La Sapienza", Rome.
- 1986-1989 Full Professor, Chair of General Pathology, Medical School, University of L'Aquila, L'Aquila.
- 1988-1993 Head, Ph.D. Course of Biotechnology, University of L'Aquila, L'Aquila.
- 1990-present Full Professor, Chair of Immunology, Medical School, University of Rome " La Sapienza", Rome, Italy.
- 1991-2000 Head of Pathophysiology Laboratory, "Regina Elena" Cancer Institute, Rome.
- 1993-2011 Head, Ph.D. Course of Immunology, University of Rome "La Sapienza", Rome.
- 1994-1997 Director of Biomedical Technologies Institute, CNR, Rome.
- 1994-2002 Vice President and President of the International Society for Natural Immunity
- 1994-2009 Member, Scientific Council "Istituto Pasteur - Fondazione Cenci Bolognetti", University of Rome "La Sapienza".
- 1996-2001 Member, Scientific Council "Center for the Study of Immunogenetics and Experimental Oncology", C.N.R., Turin.
- 1997-1999 Member of the National Committee for A.I.D.S. (Department of Health).
- 1998-2001 President Scientific Council of Biomedical Technologies Institute, CNR, Rome.
- 2000-2003 Member of AIRC Grant Committee.
- 2001-present Member of " European Molecular Biology Organization (EMBO).
- 2001-present Principal Investigator of the Centre of Excellence "Molecular Biology. and Medicine" (BEMM) of University of Rome "La Sapienza".
- 2002-2008 Council Officer of the Italian Society for Immunology.
- 2003-present Director of the Specialty School in Clinical Pathology.
- 2003-2013 Vice President Master Course in Medical Biotechnologies, Sapienza University of Rome.
- 2004-2007 Member of EMBO Fellowship Committee.
- 2005-2012 Member of AIRC Advisory Board.
- 2006-2014 Coordinator of PhD program in Molecular Biology and Medicine.
- 2007-2010 Member of the National Committee for Health Research.
- 2009-2015 Member of the Patent Committee, University of Rome "La Sapienza".
- 2009-present Scientific Director Istituto Pasteur Institute-Fondazione Cenci Bolognetti, Rome.
- 2010-present Head Department of Molecular Medicine, University of Rome "La Sapienza".

2010-2011	Member of the Evaluation Board for MIUR-PRIN Projects 2009 for Medical Sciences.
2011-2016	Head, Ph.D. Course of Immunology, Hematology and Rheumatology.
2011-2017	Member of the Board of Sapienza Advanced School.
2011-2017	ERC-starting grant Committee panel Infection and Immunity.
2012-2017	Representative for Europe Region at the Institut Pasteur International Network Executive Bureau and at the Board of Pasteur International Network Association.
2014-2017	Vice President Italian Society of Immunology, Clinical Immunology and Allergology (SIICA)
2012-2018	Member of GAVI (Global Alliance for Vaccination and Immunization) Board as Italian representative.
2010-present	Member of Academia Europaea.
2013-present	President Master Course in Medical Biotechnologies.
2013-present	Italian delegate MIUR Horizon 2020 SC1 Health, Demographic change and Wellbeing.
2014-present	Member “Consiglio di Indirizzo e Verifica” Istituti Fisioterapici Ospitalieri (IFO), Roma
2015-present	Member of the Education Committee of International Union Immunological Societies (IUIS)
2015-present	Member of the Council of International Union Immunological Societies (IUIS)
2016-present	Member Assemblée des Cent de l’Institut Pasteur, Paris
2017-present	Head, Ph.D. Course in Innovation in immuno-mediated and hematological disorders
2017-present	Honorary Fellow of Sapienza Advanced School
2017-present	President Italian Society of Immunology, Clinical Immunology and Allergology (SIICA)

Dr. Santoni is member of the following scientific societies:

Academia Europaea

European Molecular Biology Organization (EMBO)

American Association of Immunologists (A.A.I.)

International Society of Natural immunity

Società Italiana di Immunologia, Immunologia Clinica ed Allergologia (S.I.I.C.A.)

Società Italiana di Patologia e Medicina Traslazionale (SIPMET)

Editor in Chief of Immunology Letters (2010-2012), Member of the Editorial Board of the European Journal of Immunology and the American Journal of Reproductive Immunology, Frontiers in Immunology, referee of several international journals such as Journal of Immunology, Blood, Cancer Research, Clinical Cancer Research, Immunology, Journal of Leukocyte Biology.

She is recipient of grants from several research agencies including MIUR (Coordinator of a national program from 1987), CNR, Ministry of Health, AIRC and the European Union. Author of more than 250 publications in highly qualified international journals and invited speaker in numerous national and international scientific congresses. Hirsch index = 58

SCIENTIFIC INTERESTS

Over the last years, the main interests of Dr. Santoni's laboratory have been focused on understanding the role of the intracellular signaling pathways triggered by several surface activation/adhesion receptors in NK cell functions. She has first demonstrated that integrins function as signaling receptors in NK cells.

More recently she has been interested in analysing the molecular mechanisms regulating the expression of NK cell activating receptor ligands on both normal and neoplastic cells. In particular, she first demonstrated that chemotherapeutic drugs stimulate the up-regulation of NKG2D and DNAM-1 ligands on multiple myeloma cells through the activation of the DNA damage response and induction of a cell senescence program. These findings suggest that NK cells are a key component of lymphoid stress surveillance response against tumor cells and that NK cell-based chemoimmunotherapy represents a promising approach to treat malignancies.